BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther 2022;7:146. [PMID: 35504917 DOI: 10.1038/s41392-022-00996-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu T, Li J, Hu Y, Tang LV. Hematological Questions in Personalized Management of COVID-19 Vaccination. JPM 2023;13:259. [DOI: 10.3390/jpm13020259] [Reference Citation Analysis]
2 Raslan MA, Raslan SA, Shehata EM, Mahmoud AS, Sabri NA, Alzahrani KJ, Alzahrani FM, Alshammeri S, Azevedo V, Lundstrom K, Barh D. COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful? Vaccines 2023;11:214. [DOI: 10.3390/vaccines11020214] [Reference Citation Analysis]
3 Shao H, Lin XQ, Chen Y, Lv L, Ying CQ, Tung TH, Zhu JS. Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China. Hum Vaccin Immunother 2023;:2158012. [PMID: 36606519 DOI: 10.1080/21645515.2022.2158012] [Reference Citation Analysis]
4 Li X, Yin Y, Cui Q, Huang W, Zou Q, Shen T. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study. J Med Virol 2023;95:e28279. [PMID: 36329634 DOI: 10.1002/jmv.28279] [Reference Citation Analysis]
5 He ST, Qin H, Guan L, Liu K, Hong B, Zhang X, Lou F, Li M, Lin W, Chen Y, He C, Liu F, Lu S, Luo S, Zhu S, An X, Song L, Fan H, Tong Y. Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model. J Med Virol 2023;95:e28281. [PMID: 36329614 DOI: 10.1002/jmv.28281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang M, Hussain A, Yang H, Zhang J, Liang XJ, Huang Y. mRNA-based modalities for infectious disease management. Nano Res 2023;16:672-91. [PMID: 35818566 DOI: 10.1007/s12274-022-4627-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang H, Jin H, Yan F, Song Y, Dai J, Jiao C, Bai Y, Sun J, Liu D, Wang S, Zhang M, Lu J, Huang J, Huang P, Li Y, Xia X, Wang H. An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. Virol Sin 2022:S1995-820X(22)00212-7. [PMID: 36587795 DOI: 10.1016/j.virs.2022.12.006] [Reference Citation Analysis]
8 He S, Wu K, Cheng Z, He M, Hu R, Fan N, Shen L, Li Q, Fan H, Tong Y. Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions. MedComm 2022;3. [DOI: 10.1002/mco2.196] [Reference Citation Analysis]
9 Tang H, Ke Y, Liao Y, Bian Y, Yuan Y, Wang Z, Yang L, Ma H, Sun T, Zhang B, Zhang X, Wu M, Zhu J. Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix. Virol Sin 2022;37:860-73. [PMID: 36414178 DOI: 10.1016/j.virs.2022.11.005] [Reference Citation Analysis]
10 Mudenda S, Ngalande N, Mukosha M, Hikaambo CN, Daka V, Matafwali SK, Banda M, Mfune RL, Mayoka G, Witika BA. Knowledge and practices toward COVID-19 among healthcare students: A cross-sectional study at the University of Zambia. Front Public Health 2022;10:1028312. [PMID: 36530704 DOI: 10.3389/fpubh.2022.1028312] [Reference Citation Analysis]
11 Ling Z, Yi C, Sun X, Yang Z, Sun B. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Sci China Life Sci 2022. [PMID: 36443513 DOI: 10.1007/s11427-022-2215-6] [Reference Citation Analysis]
12 Wu Y, Li H, Wang Y. The Re-Emergence of COVID-19 in 2022 Has Affected People’s Views on Vaccines. Vaccines 2022;10:1974. [DOI: 10.3390/vaccines10111974] [Reference Citation Analysis]
13 Casseb SMM, Khayat AS, de Souza JES, de Oliveira EHC, Dos Santos SEB, da Costa Vasconcelos PF, de Assumpção PP. Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms. Genes 2022;13:2147. [DOI: 10.3390/genes13112147] [Reference Citation Analysis]
14 Sano H, Imagawa A. Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic. Biology 2022;11:1662. [DOI: 10.3390/biology11111662] [Reference Citation Analysis]
15 Sun Y, Zou Y, Wang H, Cui G, Yu Z, Ren Z. Immune response induced by novel coronavirus infection. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.988604] [Reference Citation Analysis]
16 Cristina Diaconu C, Madalina Pitica I, Chivu-economescu M, Georgiana Necula L, Botezatu A, Virginia Iancu I, Iulia Neagu A, L. Radu E, Matei L, Maria Ruta S, Bleotu C. SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. Infectious Diseases 2022. [DOI: 10.5772/intechopen.107137] [Reference Citation Analysis]
17 Nagpal D, Nagpal S, Kaushik D, Kathuria H. Current clinical status of new COVID-19 vaccines and immunotherapy. Environ Sci Pollut Res Int 2022. [PMID: 36063274 DOI: 10.1007/s11356-022-22661-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, Fan H. Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention. MedComm 2022;3. [DOI: 10.1002/mco2.172] [Reference Citation Analysis]
19 Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Tarique M, Suhail M, Naz H, Muhammad N, Tabrez S, Zughaibi TA, Abuzenadah AM, Hashem AM, Shankar H, Saini C, Sharma A. Where do T cell subsets stand in SARS-CoV-2 infection: an update. Front Cell Infect Microbiol 2022;12:964265. [DOI: 10.3389/fcimb.2022.964265] [Reference Citation Analysis]
21 Olivera-ugarte S, Bolduc M, Laliberté-gagné M, Blanchette L, Garneau C, Fillion M, Savard P, Dubuc I, Flamand L, Farnòs O, Xu X, Kamen A, Gilbert M, Rabezanahary H, Scarrone M, Couture C, Baz M, Leclerc D. A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. Nanomedicine: Nanotechnology, Biology and Medicine 2022;44:102584. [DOI: 10.1016/j.nano.2022.102584] [Reference Citation Analysis]
22 Wang Z, Li S, Huang B. Alveolar macrophages: Achilles' heel of SARS-CoV-2 infection. Signal Transduct Target Ther 2022;7:242. [PMID: 35853858 DOI: 10.1038/s41392-022-01106-8] [Reference Citation Analysis]
23 Yan Y, Davgadorj C, Lyu C, Zhang S, Qiu Y. Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study. J Infect 2022:S0163-4453(22)00407-8. [PMID: 35803384 DOI: 10.1016/j.jinf.2022.06.032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Khokhar F, Khan A, Hussain Z, Yu J. Small Fiber Neuropathy Associated With the Moderna SARS-CoV-2 Vaccine. Cureus 2022;14:e25969. [PMID: 35812635 DOI: 10.7759/cureus.25969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]